Please assess the completion status of the following clinical trial:

Trial Title: TAK-954 in Critically Ill Participants With Enteral Feeding Intolerance (EFI)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~1. Has at least a size 12-(french size) Fr nasogastric or orogastric tube with its tip at least 10 centimeter (cm) below the esophagogastric junction confirmed radiologically (the tip of the tube must be in the body or the antrum of the stomach and not in the fundus).~2. Is intubated and mechanically ventilated in the ICU.~3. Is expected to remain alive, mechanically ventilated, and receive continuous enteral feeding for \>=48 hours following randomization.~4. Have EFI, defined as a single GRV measurement of \>=250 mL with vomiting/retching within the last 24 hours, or a single GRV measurement of \>=500 mL with or without vomiting/retching within the last 24 hours.~Exclusion Criteria:~1. Is under consideration for withdrawal of life-sustaining treatments within the next 72 hours.~2. Has had major esophageal or gastric surgery or direct luminal trauma on this admission (participants with lower abdominal surgery are not excluded unless enteral feeding is contraindicated).~3. Has mechanical bowel obstruction, short bowel syndrome, or the presence of an active gastric pacemaker.~4. Have pre-existing hepatic disease that meets Child-Pugh Class B (moderate; total score 7 to 9 points) or C (severe; total score 10 to 15 points).~5. Has been admitted primarily for treatment of a drug overdose.~6. Has a presence of a post-pyloric tube in place at Randomization that may be used for enteral nutrition.~7. Is receiving parenteral nutrition (PN) at Screening.~8. Is in diabetic ketoacidosis or non-ketotic hyperosmolar coma.~9. Has a different nutrient requirement than allowed in feeding protocol.(outside a range of 1.2 to 2 gram per kilogram per day \[g/kg/day\] of proteins and up to 1.5 kilocalorie per milliliter \[kcal/mL\]).

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Group A: TAK-954 0.1 mg (Type: EXPERIMENTAL): TAK-954 0.1 milligram (mg), intravenously, administered as 60 minute-infusion, once daily along with 2 milliliter (mL) normal saline injection, intravenously, three times a day for a minimum of 5 days up to a maximum of 14 days.
- Group B: TAK-954 0.3 mg (Type: EXPERIMENTAL): TAK-954 0.3 mg, intravenously, administered as 60 minute-infusion, once daily along with 2 mL normal saline injection, intravenously, three times a day for a minimum of 5 days up to a maximum of 14 days.
- Group C: TAK-954 1.0 mg (Type: EXPERIMENTAL): TAK-954 1.0 mg, intravenously, administered as 60 minute-infusion, once daily along with 2 mL normal saline injection, intravenously, three times a day for a minimum of 5 days up to a maximum of 14 days.
- Group D: Metoclopramide 10 mg (Type: ACTIVE_COMPARATOR): Metoclopramide 10 mg, injection, intravenously, three times a day along with 100 mL normal saline 60-minute infusion, intravenously, once daily for a minimum of 5 days up to a maximum of 14 days.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues